Q-omics provides the consensus-scored KRT125P profile across patient tissues and cancer cell-line models. KRT125P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, KRT125P is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, KRT125P RNA expression shows 5,575 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, and STAD as cancer lineages where KRT125P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT125P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT125P survival associations across molecular data types. KRT125P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT125P RNA expression–survival associations across cancer types. High KRT125P expression shows unfavorable associations in THCA, KIRC, COAD, UCS, UCEC and GBM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for KRT125P RNA expression.
This table summarizes KRT125P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT125P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT125P shows higher tumor expression in STAD. The STAD box plot shows higher KRT125P RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .011).
This table shows molecular features associated with KRT125P in patient tissues and cancer cell lines. In patient samples, KRT125P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
